Immunex Files Supplemental NDA for NOVANTRONE
. . .SEATTLE - Immunex Corporation (NASDAQ:IMNX) announced today that it has filed a.supplemental NDA with the U.S. Food and Drug Administration (FDA) for expanded.labeling for NOVANTRONE® (mitoxantrone for injection concentrate) for the.treatment of patients with secondary progressive Multiple Sclerosis (MS).. . "There are 120,000 patients with secondary progressive MS for whom there...Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
. . .SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has.launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in.the most common form of kidney cancer, renal cell carcinoma. The company is.continuing the development of CD40L based on results of a multi-dose Phase I.trial of the drug in advanced cancer patients.. . The Phase I study, which evalua...Immunex's TRAIL Molecule Shows Potential As Anti-Tumor Agent
.SEATTLE, WA -- A preclinical study published in the journal Nature Medicine.today demonstrated that TRAIL (TNF-related apoptosis-inducing ligand) suppresses.tumor growth, and in some instances caused complete remission of tumors, by a.direct and specific mechanism. The work described in the journal was conducted.in mice by scientists at Immunex Corporation (NASDAQ:IMNX). . .In the study, grou...